- Partnership combines QIAGEN's QIAseq panels, CLC
LightSpeed, and QCI Interpret software to support Element's AVITI
System users in genomic analysis
- Element and QIAGEN are advancing genomic applications with
innovative technology and complete next-generation sequencing (NGS)
workflows for researchers
- Partnership to accelerate discovery, enhance cost
efficiencies, and improve turnaround times for genomic applications
in the scientific community
VENLO, Netherlands, and SAN
DIEGO, Nov. 2, 2023 /PRNewswire/ -- QIAGEN
(NYSE: QGEN; Frankfurt Prime Standard: QIA) and Element
Biosciences, Inc. today announced a strategic partnership to offer
comprehensive next-generation sequencing (NGS) workflows for the
AVITI™ System, an innovative sequencing platform based on Element's
novel Avidity sequencing chemistry.
Element's AVITI System, a flexible benchtop sequencer with
industry-leading performance and cost, delivers high quality,
affordable data for any application, at a range of scale. For
customers using the AVITI System, QIAGEN provides Sample to Insight
NGS workflows with validated QIAseq panels and integrated
bioinformatic solutions, including CLC LightSpeed and QCI Interpret
software.
"The collaboration between QIAGEN and Element Biosciences
delivers unprecedented insights across various genomic applications
to our customers worldwide. Researchers are increasingly searching
for complete solutions and workflows from sample to insight, and we
are committed to advancing the field together by providing
innovative technology and applications that help researchers
accelerate discovery," said Nitin
Sood, Senior Vice President, Head of Life Sciences Business
Area at QIAGEN.
Yaron Hakak, PhD, Senior Vice
President of Corporate and Business Development at Element
Biosciences, added: "Element and QIAGEN share the goals of offering
flexible, cost-effective, and high-performance solutions to our
customers. Jointly promoting the combined workflow will help
us serve an expanded customer base with the backing of a global
genomic powerhouse like QIAGEN."
QIAGEN's QIAseq panels enable efficient and accurate NGS library
preparation. The QIAseq miRNA Library Kit, the QIAseq xHYB
Actionable Exome Panel, and the QIAseq Targeted DNA Pro Panel have
been validated on the AVITI sequencer with robust performance, high
specificity, and coverage uniformity, as well as consistent variant
detection.
LightSpeed, a new module for QIAGEN CLC Genomics Workbench
Premium, enables AVITI System users to perform cost-effective whole
genome sequencing (WGS) secondary analysis with exceptional
runtimes. QCI Interpret, a fully customizable software solution,
facilitates NGS variant interpretation and reporting for oncology
and hereditary applications, with over 3 million reports
issued.
"There is a huge potential for NGS to deliver on the vision of
precision medicine. One of the greatest barriers to ubiquitous
adoption and use is the efficient downstream analysis and
interpretation of processed samples," said Jonathan Sheldon, PhD, Senior Vice President of
QIAGEN Digital Insights. "We are pleased to partner with Element
Biosciences to deliver joint solutions that enable customers to
rapidly adopt, automate, and scale their NGS needs with higher cost
efficiencies and faster turnaround times."
More information on the NGS workflow for the AVITI system can be
found
here: https://www.elementbiosciences.com/products/aviti
Element will present new data from customers and highlight
AVITI's higher accuracy sequencing for research applications at the
American Society of Human Genetics (ASHG) 2023 annual meeting. More
information:
https://www.elementbiosciences.com/events/meet-element-at-ashg-2023
About Element Biosciences, Inc.
Element Biosciences is
a multi-disciplinary life science company focused on developing
disruptive DNA sequencing technology for research markets. Through
innovating every fundamental element of a sequencing system,
Element empowers customers with affordable, high-quality data and
an improved user experience, which in turn will accelerate
scientific discoveries and broaden the use of genomic research. To
learn more about Element, please
visit www.elementbiosciences.com or follow Element on LinkedIn
and X.
Element Biosciences Media Contact:
Kristi Heim
kristi.heim@elembio.com
About QIAGEN
QIAGEN N.V., a Netherlands-based holding company, is the
leading global provider of Sample to Insight solutions that enable
customers to gain valuable molecular insights from samples
containing the building blocks of life. Our sample technologies
isolate and process DNA, RNA and proteins from blood, tissue and
other materials. Assay technologies make these biomolecules visible
and ready for analysis. Bioinformatics software and knowledge bases
interpret data to report relevant, actionable insights. Automation
solutions tie these together in seamless and cost-effective
workflows. QIAGEN provides solutions to more than 500,000 customers
around the world in Molecular Diagnostics (human healthcare) and
Life Sciences (academia, pharma R&D and industrial
applications, primarily forensics). As of June 30, 2023,
QIAGEN employed more than 6,100 people in over 35 locations
worldwide. Further information can be found
at http://www.qiagen.com.
Contacts QIAGEN:
Investors
Relations
|
|
Public
Relations
|
|
John Gilardi
|
+49 2103 29
11711
|
Thomas
Theuringer
|
+49 2103 29
11826
|
Phoebe Loh
|
+49 2103 29
11457
|
Daniela
Berheide
|
+49 2103 29
11676
|
e-mail:
ir@QIAGEN.com
|
|
e-mail:
pr@QIAGEN.com
|
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/qiagen-and-element-biosciences-partner-to-offer-complete-next-generation-sequencing-workflows-for-the-aviti-system-301975076.html
SOURCE Element Biosciences